Moreover, there was a greater reduction in tumor volume observed in patients with MTAP-negative mesotheliomas compared to those with MTAP-positive mesotheliomas, suggesting that CDKN2A and MTAP codeletions may select for patients who will derive a greater benefit from abemaciclib [53]. This evidence concerns the gene CDKN2A and mesothelioma.